



THERE IS MORE TO A MIGRAINE THAN JUST A BAD HEADACHE

**An Overview of the Burden of Disease
and Its Impact on the Workforce**

abbvie

Migraine Is a Common Chronic Condition¹



Over 37 million Americans suffer from migraine,² with incidence peaking during the most productive professional years (ages 25-55 years).³


- Of the 37 million, 2% experience chronic migraine, with 15 or more migraine days per month²



[In the United States, 1 in 4 households has someone dealing with migraine.²



[For people aged 15 to 49 years, migraine is the top cause of disability.⁴



Women suffer from migraine at a disproportionate rate compared with men, with prevalence estimated at 18% vs 6%, respectively.³

- Hormonal changes are believed to be the cause of the disproportionate rate, with up to **60% of these women having migraine attacks around their menstrual cycle**⁵



[**43% of women and 18% of men will experience migraine at some point in their lives.**^{6,*}


Migraine Is a Primary Headache Disorder Without an Underlying Cause⁷

A migraine's frequency determines its type⁸

Migraine is subdivided into types (**episodic or chronic**), depending on the number of monthly headache days (MHDs).

- **Episodic** migraine occurs **less than 15 days per month**
- **Chronic** migraine occurs **15 or more days per month for more than 3 months**[†]

Percentage of Patients Experiencing Migraine by MHDs⁹



[A US study found that chronic migraine-related costs were higher than episodic migraine-related costs. The average annual total costs associated with chronic migraine vs episodic migraine were \$8,243 (SD, \$10,646) vs \$2,649 (SD, \$4,634), respectively ($P < 0.001$).^{10,‡}

SD=standard deviation.

*Cumulative lifetime incidence.⁶

†Symptoms of migraine headache on at least 8 days per month.⁸

‡Web-based questionnaire surveyed patients with migraine (chronic, n=103; episodic, n=1,101) regarding healthcare resource utilization (direct costs) that occurred due to their headaches and headache-related disability (indirect costs) over the last 3 months. Annual direct costs were calculated by multiplying the frequency of use by its estimated unit cost. Indirect costs applied to losses in work or school time attributable to absenteeism or presenteeism. Costs presented in 2013 US dollars. Key study limitations: results were dependent on participant recall and not verified.¹⁰



Differences in Episodic vs Chronic Migraine

Migraine Classifications Are Determined by Symptoms



According to the International Classification of Headache Disorders (ICHD), there are 2 major migraine classifications¹¹:

Migraine with aura is characterized by **1 or more of the following symptoms** that develop gradually¹²:

- ✓ Flashes of light
- ✓ Blind spots and other vision changes
- ✓ Tingling in your hand(s) or face

Migraine without aura is characterized by¹³:

- ✓ **Moderate to severe, throbbing headache on 1 side of the head**
- ✓ Often, aggravation by routine physical activity
- ✓ Sensitivity to light and sound and/or nausea with or without vomiting



Approximately one-third of people with migraine experience migraine with aura.⁷



The distinction between episodic and chronic migraine drives treatment choices, whereas the distinction between migraine with and without aura may have implications regarding comorbidity, assessment of risk factors, and prognosis.⁷



As part of a migraine education program, include prevalence statistics and general education on migraine to raise awareness of this common chronic condition.

It Can Be Difficult to Diagnose Migraine⁷



There are no blood, imaging, or interventional tests available to confirm a migraine diagnosis; therefore, migraine is diagnosed based on clinical symptoms. Healthcare providers (HCPs) use screening questionnaires and symptoms to determine if a patient is suffering from migraine.

- Only **56%** of people with migraine **receive a diagnosis**¹⁴



Only one-third of individuals with migraine speak with their HCPs about their headaches. In a population-based survey for migraine diagnosis, approximately 50% of individuals with migraine were not aware of their diagnosis.^{15,16}

Racial Disparities in Migraine Care Exist¹⁷

Among patients with headaches:

- Only **46% of Black patients seek help from HCPs** compared with **72% of White patients**

Black patients vs White patients




This is due to a variety of factors such as discrimination, cost, mistrust of the healthcare system, and lack of access.

- Only **47% of Black patients have an official headache diagnosis** compared with **70% of White patients**



This is significant because patients without a migraine diagnosis cannot receive migraine-specific therapy.

- Only **14% of Black patients receive prescriptions for acute treatment**, compared with **37% of White patients**



➔ To promote migraine awareness and early detection, post a migraine screening questionnaire on your company's employee resource site.

- Include additional resources related to appropriate connections to care to drive timely treatment
- Provide directions on how to access the resource site in your employee migraine education program


➔ In companies that have established on-site medical homes, consider implementing the use of migraine screening questionnaires, such as the ID Migraine tool, to prompt timely next-step care planning.

- Employees with results indicative of migraine should visit the company's resource site to find additional migraine resources, as well as information about migraine specialists in the company's network

Migraine Attacks Present in Phases, Each Posing Its Own Burden, Impacting Your Employee's Quality of Life¹⁸

Migraine is considered the second most disabling disease in the world, yet it is often underrecognized and undertreated. As a result, patients suffering from migraine may have increased functional impairment and reduced quality of life.¹⁹

The 4 Phases of Migraine Attacks²⁰



Risk factors for migraine disease progression²¹⁻²³:

- **Nonmodifiable:** age, gender (female), lower socioeconomic status, marital status (previous marriage)
- **Modifiable:** obesity, sleep problems, comorbid pain, head or neck injury, major life events, smoking, caffeine intake, depression, medication overuse, poor acute attack management



Approximately 80% of individuals with migraine report stress as the most common trigger.²⁴

The Migraine Disease Report 2021, assessing stigma and burden from a human resources (HR) and patient perspective, concluded (from n=309 responses)²⁵:

64% of HR professionals report that employees who suffer from migraine disease have **sometimes, often, or always worked during migraine attacks**

However, only **1%** of participants say **migraine attacks do not impact their ability to work**

48% of HR professionals believe that migraine disease **can qualify as a disability in their organization**

However, **39%** say many direct supervisors in their organization **do not consider migraine attacks a valid reason to miss work**

And **36%** say many direct supervisors in their organization **do not view the disease as debilitating**



Ensure HR/supervisors are aware that resources are available to help employees experiencing migraine. Provide them with information on how to connect employees to appropriate migraine care.

Comorbidities Contribute to the Overall Health Burden in People Living With Migraine²⁶

There are many comorbidities associated with migraine



Mental health disorders: depression, anxiety, panic disorders, personality disorder, suicide attempts



Sleep conditions: insomnia, restless legs syndrome, sleep apnea, poor quality and duration of sleep



Chronic pain conditions: fibromyalgia, arthritis



Cardiovascular disorders: stroke, myocardial infarction



Inflammatory conditions: allergic rhinitis, asthma



Neurologic disease: epilepsy



Many comorbidities have been identified as risk factors for the progression from episodic migraine to chronic migraine.²⁶

- The combination of multiple comorbidities, or “multimorbidity,” has also been linked to medication overuse and new onset of chronic migraine.



Comorbid and Co-occurring Conditions in Migraine and Associated Risk of Increasing Headache Pain Intensity and Frequency

Besides the Physical Effects of Migraine, Individuals With Migraine Also Experience Psychological Effects²⁷

According to a survey of 5,692 US adults:



52% of patients with moderate to severe migraine-related disability have experienced **depression**^{27,*}



43% of patients with moderate to severe migraine-related disability have experienced **anxiety**^{27,*}

Those with migraine also report an effect on their families and relationships²⁸:



- **64%** report an **effect on their private life**²⁸
- **37%** report **stress in their spousal relationship**²⁹
- **~50%** have experienced a **reduction in family activities**²⁹

*61% have increased risk of moderate/severe disability with depression and anxiety.²⁷

Economic Impacts of Migraine Are High for Employees, Employers, and Payers³⁰

The Migraine Research Foundation estimates that **157 million workdays are lost annually** to migraine. Moreover, the American Headache Society Consensus Statement states that migraine is associated with a substantial financial burden, with an estimated **\$27 billion in annual costs** reported in the United States.^{3,31}

A 2018 retrospective cohort analysis estimating the economic burden of migraine found that patients with migraine in the United States had increased all-cause healthcare costs and decreased productivity when compared with people without migraine.^{32,*}




Direct costs³²

The mean annual total (direct + indirect) all-cause costs were \$8,924 greater for patients with migraine than for those without migraine (\$22,304 vs \$13,381, respectively).

- Direct healthcare costs accounted for approximately three-quarters of the total cost and were \$6,575 greater for patients with migraine than for those without migraine (\$11,010 [SD, \$19,663] vs \$4,436 [SD, \$13,081]; $P < 0.01$)

Composition of the \$6,575 Direct Healthcare Costs³²



Indirect costs³²

Total unadjusted mean annual indirect all-cause costs were \$2,350 higher for patients with migraine than for those without migraine (\$11,294 vs \$8,945, respectively).

- Of patients with workplace absence, short-term disability, and long-term disability, those with migraine missed almost 9 more days of work each year than those without migraine (mean days absent=37.0 vs 28.2, respectively)



In the 2018 My Migraine Voice global survey of 11,266 adults with migraine, 70% of people reported that migraine affects their professional life.²⁸

*Truven Health MarketScan® Commercial Claims and Encounters (Commercial) and the Health and Productivity Management (HPM) databases between January 1, 2007, and June 30, 2013, were used in this analysis. Study included 71,742 adults with migraine and 1:1 matched individuals without migraine with 12 months of continuous enrollment before (baseline period) and after (follow-up period) the day they received a migraine diagnosis and/or medication (index). Matching was based on demographic variables and index date. The date of first diagnosis/treatment of migraine was defined as the index date for the migraine cohort. Chi-square tests were conducted on categorical measures and t-tests on continuous measures. Costs in 2014 US dollars. **Key study limitations:** Claims analyses are subject to coding errors. Coding for migraine lacks specificity to determine migraine severity, which may limit the ability to account for the full burden of migraine. Research databases used for the present study were limited to employer-sponsored health insurance; therefore, findings may not be generalizable to individuals with other types of insurance or uninsured individuals.

Healthcare Utilization Rates and Costs May Increase With Migraine Severity

Patients with treated migraine with ≥ 4 MHDs compared with those without migraine had^{33,*}



5.5% higher absenteeism (mean [SD], 11.8% [20.7%] vs 6.3% [17.8%] within the past 7 days, respectively; $P=0.03$).

- **Estimated annual mean costs were \$2,597 more** (mean [SD], \$4,134 [\$8,035] vs \$1,537 [\$5,078], respectively; $P=0.003$)



18.5% higher presenteeism (mean [SD], 36.0% [31.5%] vs 17.5% [25.5%] within the past 7 days, respectively; $P<0.001$).

- **Estimated annual mean costs were \$6,409 more** (mean [SD], \$10,637 [\$11,781] vs \$4,228 [\$7,195], respectively; $P<0.001$)



3.2 more all-cause HCP visits during previous 6 months (mean [SD], 7.6 [9.6] vs 4.4 [7.7] visits, respectively; $P<0.001$).

- **Estimated annual mean costs were \$6,337 more** (mean [SD], \$15,967 [\$20,786] vs \$9,630 [\$15,486], respectively; $P<0.001$)



0.2 more all-cause emergency department visits during the last 6 months (mean [SD], 0.5 [1.2] vs 0.3 [0.9] visits, respectively; $P=0.03$).

- **Estimated annual mean costs were \$784 more** (mean [SD], \$1,684 [\$4,160] vs \$900 [\$3,129], respectively; $P=0.035$)



A 2018 US retrospective cohort analysis estimating the economic burden of migraine found that patients with migraine were 3 times more likely to have an all-cause annual inpatient admission (6,164 vs 2,115 admissions; $P<0.01$) and more than twice as likely to have an all-cause annual emergency department visit (24,258 vs 10,287 visits; $P<0.01$) than people without migraine.^{32,†}



Review your annual utilization data, including codes for chronic headaches and migraine disorders, to understand the burden of migraine within your employee population, including use of the emergency department for care.

- Consult with your healthcare plan advisors to strategize how best to improve care



Review your provider network and prior authorization process to ensure your employees have timely access to migraine specialists and/or a migraine-treating primary care provider.

*Retrospective cross-sectional study using data from the 2016 web-based US National Health and Wellness Survey compared the burden of migraine from adults self-reporting a migraine diagnosis by an HCP and ≥ 4 MHDs while using acute and/or preventive prescription migraine medications ($n=197$) vs propensity score-matched adult controls without migraine ($n=197$). Absenteeism was defined as percentage of work time missed due to one's health in the last 7 days; presenteeism was defined as percentage of impairment or reduced productivity while at work in the previous 7 days due to one's health. **Key study limitations:** Patient-reported survey data cannot be independently verified by an HCP or medical record. As a result, inaccurate recall, misunderstandings, or false reporting may introduce potential bias and limit interpretation of the data.

†Truven Health MarketScan. Commercial Claims and Encounters (Commercial) and the Health and Productivity Management (HPM) databases between January 1, 2007, and June 30, 2013, were used in this analysis. Study included 71,742 adults with migraine and 1:1 matched individuals without migraine with 12 months of continuous enrollment before (baseline period) and after (follow-up period) the day they received a migraine diagnosis and/or medication (index). Matching was based on demographic variables and index date. The date of first diagnosis/treatment of migraine was defined as the index date for the migraine cohort. Chi-square tests were conducted on categorical measures and t-tests on continuous measures. Costs in 2014 US dollars. **Key study limitations:** Claims analyses are subject to coding errors. Coding for migraine lacks specificity to determine migraine severity, which may limit the ability to account for the full burden of migraine. Research databases used for the present study were limited to employer-sponsored health insurance; therefore, findings may not be generalizable to individuals with other types of insurance or uninsured individuals.

Migraine Treatment Strategies Are Evolving




Migraine management begins with establishing treatment goals³

An effective migraine treatment plan may include both preventive and acute medications.

The goals of migraine prevention and treatment strategies include:

- ✓ Reducing attack frequency, severity, duration, and disability
- ✓ Improving responsiveness to and avoiding escalation in use of acute treatment
- ✓ Improving function and reducing disability
- ✓ Reducing reliance on poorly tolerated, ineffective, or unwanted acute treatments
- ✓ Enabling patients to manage their own disease to enhance a sense of personal control
- ✓ Reducing headache-related distress and psychological symptoms



Like other chronic conditions, migraine treatment is evolving³⁴

In 2018, the US Food and Drug Administration approved the first calcitonin gene-related peptide (CGRP) inhibitors, developed to prevent migraine attacks.

- Individuals with migraine have higher levels of CGRP in their blood



Gaps remain in optimal migraine care as individuals cycle through multiple preventive options



A cross-sectional, longitudinal, internet-based study administered from 2012-2013 and published in 2020 showed that among 2,388 individuals living with migraine, more than 36% reported using opioid medications to treat headaches.³⁵



Work with your pharmacy benefit advisors to evaluate your current migraine treatment formulary to ensure employee access to all migraine treatment for optimized care in your migraine population.

Migraine Employee Education Programs Can Increase Engagement and Self-management



Employers can provide support by taking action to prevent migraine among employees and reducing productivity losses associated with migraine attacks.

Employer-led migraine support services

- Educate around migraine prevention and management techniques, such as identifying and avoiding migraine triggers and optimizing medication use¹
- Optimize the work environment to reduce and eliminate migraine triggers, such as bright lights, loud noises, strong odors, poor air quality, and restricted access to water and restroom breaks¹
- Provide migraine management services such as gym access, same-day/on-site occupational services, and screening programs¹



Researchers have found that providing employees with gym access decreased migraine attacks, and providing same-day occupational health services for migraine treatment reduced productivity losses otherwise caused by migraine.¹



According to [recent studies](#), instituting migraine education programs was associated with a 29%-36% increase in productivity owing to fewer workdays lost due to migraine attacks, fewer days worked with migraine attacks, and an increase in effectiveness on days when employees worked with migraine attacks.¹



Metro Nashville Public School System Implements Virtual Employee Migraine Education Program to Empower Employees With Information to Better Manage Their Condition



Impact of Employer-based Migraine Education Program on Resource Utilization and Cost Burden

The migraine education program that served as the foundation of the Metro Nashville Public School System program is available from Migraine at Work (migraineatwork.org), which is sponsored in part by AbbVie.




Develop a migraine education program that shares prevention and management techniques, and consider opportunities to adjust the work environment to minimize migraine-related triggers.

What do migraine management leaders* do differently?²⁵

According to the Migraine Disease Report 2021 assessing n=309 responses:

Migraine management leaders are **more likely** than migraine management laggards to offer health insurance that covers migraine disease.²⁵



VS

Migraine management leaders are **less likely** to have restrictions on medications to treat migraine disease.²⁵

Prior authorization



VS

Quantity limits



VS

*Migraine management leaders were defined as respondents who strongly agree or agree that their organization does a good job at helping and accommodating employees with migraine disease. Migraine management laggards were defined as respondents who strongly disagree, disagree, or neither agree nor disagree that their organization does a good job at helping and accommodating employees with migraine disease. In actuality, these numbers may be much higher.²⁵

Raising Awareness and Improving the Long-Term Care for Employees With Migraine: A Step-by-Step Process

STEP 1



Raise awareness of the prevalence of migraine and the burden of disease

- Create an awareness campaign that provides information on migraine prevalence, prevention, and general education
- Post a migraine screening questionnaire to your company's employee resource site and encourage employees to self-report to improve awareness and timely care connections

STEP 2



Provide access to comprehensive migraine care

- Optimize network adequacy ratios (eg, members per migraine specialist or migraine-treating primary care provider) to minimize time to treatment
- Eliminate barriers to appropriate migraine care by minimizing authorization requirements
- Review your formulary for coverage of migraine treatments and, if necessary, redesign to include all treatment options

STEP 3



Utilize employee education and care management programs for continued support

- Promote an employer-led migraine education program to increase awareness of prevention techniques and management strategies
- Optimize the work environment to minimize migraine-related triggers, and provide migraine management services such as gym access, same-day/on-site occupational services, and screening programs

Consider partnering with programs like [Migraine at Work](#) to facilitate migraine education.

- Migraine at Work is a nonprofit organization dedicated to providing employers and employees with migraine tools to build healthier, stigma-free, and more productive workplaces
- Migraine at Work offers resources and information on costs, accommodations, and educational programs to help people living with migraine go from surviving to thriving in the workplace

AbbVie's Employer Strategies Focus on Improving Workforce Health and Productivity by Addressing:



Disease State Awareness

Raising awareness of the burden and impact of disease



Access to Treatment

Establishing and expanding access to treatment



Engagement and Educational Support

Developing connections to promote engagement and educational support



For additional information and support, contact your AbbVie Account Executive.

References: 1. Begasse de Dhaem O. Migraines are a serious problem. employers can help. Published September 13, 2021. Accessed June 17, 2022. <https://hbr.org/2021/02/migraines-are-a-serious-problem-employers-can-help> 2. American Migraine Foundation. Facts about migraine. Accessed July 17, 2022. <https://americanmigraine.org/wp-content/uploads/2019/03/Facts-About-Migraine-AMF.pdf> 3. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. *Headache*. 2021;61(7):1021-1039. 4. Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting the Burden: the Global Campaign Against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. *J Headache Pain*. 2020;21(1):137. 5. Pavlović JM, Stewart WF, Bruce CA, et al. Burden of migraine related to menses: results from the AMPP study. *J Headache Pain*. 2015;16:24. 6. Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Gender-related differences in migraine. *Neuro Sci*. 2020;41(suppl2):429-436. 7. Grøtta Vetvik K. Epidemiology of migraine in men and women. In: Maassen van den Brink A, MacGregor EA, eds. *Gender and Migraine*. Springer; 2019:1-15. 8. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. *Headache*. 2015;55(suppl2):103-126. 9. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). *Cephalalgia*. 2011;31(3):301-315. 10. Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. *Headache*. 2016;56(2):306-322. 11. International Headache Society. Migraine. Accessed July 17, 2022. <https://ichd-3.org/1-migraine/> 12. International Headache Society. Migraine with aura. Accessed July 17, 2022. <https://ichd-3.org/1-migraine/1-2-migraine-with-aura/> 13. International Headache Society. Migraine without aura. Accessed July 17, 2022. <https://ichd-3.org/1-migraine/1-1-migraine-without-aura/> 14. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study [published correction appears in *Headache*. 2007;47(9):1365]. *Headache*. 2007;47(3):355-363. 15. UCLA Health. Is your headache a migraine? how to tell the difference. Published September 1, 2010. Accessed June 21, 2022. <https://connect.uclahealth.org/2010/09/01/is-your-headache-a-migraine-how-to-tell-the-difference/> 16. Rai NK, Bitswa R, Singh R, Pakhre AP, Parauha DS. Factors associated with delayed diagnosis of migraine: a hospital-based cross-sectional study. *J Family Med Prim Care*. 2019;8(6):1925-1930. 17. American Migraine Foundation. Racial disparities in migraine care. Published April 11, 2022. Accessed June 17, 2022. <https://americanmigraine.org/resource-library/racial-disparities-in-migraine-care/> 18. Migraine Australia. Phases. Accessed June 17, 2022. <https://www.migraine.org.au/phases> 19. Progress in Mind. Why is migraine the second most disabling disease worldwide? Published February 22, 2020. Accessed June 17, 2022. <https://progress.im/en/content/why-migraine-second-most-disabling-disease-worldwide> 20. American Migraine Foundation. Migraine hangover. Published February 22, 2018. Accessed July 17, 2022. <https://americanmigraine.org/resource-library/migraine-hangover/> 21. Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. *Headache*. 2008;48(1):16-25. 22. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. *J Headache Pain*. 2012;13(8):615-624. 23. Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. *Neurology*. 2015;84(7):688-695. 24. Stubberud A, Buse DC, Kristoffersen ES, Linde M, Tronvik E. Is there a causal relationship between stress and migraine? current evidence and implications for management. *J Headache Pain*. 2021;22(1):155. 25. Aimerd Alliance; HR Research Institute. The state of migraine disease in the workplace 2021. Accessed June 17, 2022. https://aimerdalliance.org/wp-content/uploads/2021/02/MigraineDiseaseReport2021_Final.pdf 26. Buse DC, Reed ML, Fanning KM, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the Migraine in America Symptoms and Treatment (MAST) Study. *J Headache Pain*. 2020;21(1):23. 27. Lipton RB, Seng EK, Chu MK, et al. The effect of psychiatric comorbidities on headache-related disability in migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. *Headache*. 2020;60(8):1683-1696. 28. Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. *J Headache Pain*. 2018;19(1):115. 29. Buse DC, Scher AI, Dodick DW, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO Study. *Mayo Clin Proc*. Published online April 27, 2016. doi:10.1016/j.mayocp.2016.02.013 30. Gandhi P. Economic burden of migraine: estimated by type of migraine (EMERGE). AbbVie; April 12, 2021. 31. Curley B. Surprising ways migraine can be a financial headache, too. Published March 10, 2021. Accessed June 17, 2022. <https://www.healthline.com/health/migraine/migraine-financial-cost> 32. Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. *Headache*. 2018;58(5):700-714. 33. Buse DC, Yurgakh MS, Lee LK, Bell J, Cohen JM, Lipton RB. Burden of illness among people with migraine and ≥ 4 monthly headache days while using acute and/or preventive prescription medications for migraine. *J Manag Care Spec Pharm*. 2020;26(10):1334-1343. 34. Helmer J. CGRP inhibitors for migraine. Accessed June 17, 2022. <https://www.webmd.com/migraines-headaches/cgrp-inhibitors-for-migraine> 35. Lipton RB, Buse DC, Friedman BW, et al. Characterizing opioid use in a US population with migraine: results from the CaMEO study. *Neurology*. 2020;95(5):e457-e468.